Contraception
Conditions
Brief summary
The proposed study will investigate the relationship between genetic variants and serum contraceptive hormone levels, specifically the progestin etonogestrel. This study will provide the foundation for future pharmacogenomic investigations of more commonly used contraceptive methods with higher failure rates.
Detailed description
Approximately 700 reproductive age women (18-45) with an Etonogestrel (ENG) contraceptive implant in place for more than 1 year will be enrolled. Participants will undergo a blood draw for measurement of ENG concentration (serum) and genotyping (whole blood) and complete a questionnaire regarding their demographics and contraceptive, gynecological, and obstetrical history. The research investigators will also consent participants for use of their genetic samples and clinical data in future unspecified research. The serum samples will be de-identified for ENG analysis, which will be done using a liquid chromatography-mass spectrometry method. Additional whole blood samples collected at the enrollment visit will undergo DNA extraction. A candidate gene study was conducted using the first 350 participants. The research investigators selected 120 genetic variants for 14 target genes involved in progestin metabolism, regulation, and function for this candidate gene study. A Genome Wide Association Study will be performed using all 700 participants. Genotyping will be performed using a custom MultiEthnic Global Array chip through the Colorado Center for Personalized Medicine.
Interventions
PROCEDUREBlood draw
The Investigators will collect serum and whole blood from participants.
Sponsors
Society of Family Planning
University of Colorado, Denver
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* women of reproductive age (18-45 years) * have had an ENG contraceptive implant in place for 12-36 months
Exclusion criteria
* Use of medications or supplements in the past four weeks which could impact serum ENG levels through inhibition or induction of CYP enzymes (specifically CYP-3A4) * Medical conditions that could impact baseline liver function (e.g. hepatitis, cirrhosis) * Body mass index (BMI) less than 18.5
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of genetic variants in cases versus controls | DNA extracted from whole blood specimens will be genotyped at the conclusion of enrollment, approximately 12 months. | Genetic variants will be analyzed using a Taqman microarray chip for 120 pre-selected variants |
| Genome wide genotyping results | DNA extracted from whole blood specimens will be genotyped at the conclusion of enrollment, approximately 15 months. | Participants will undergo genotyping using a custom MEGA chip at the Colorado Center for Personalized Medicine. Imputation of the chip results will be performed. |
Countries
United States
Outcome results
None listed